Cargando…

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

OBJECTIVES: Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure rates over 8 weeks (<85%); for these patients, 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fawsitt, Christopher G., Vickerman, Peter, Cooke, Graham S., Welton, Nicky J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057278/ https://www.ncbi.nlm.nih.gov/pubmed/32113623 http://dx.doi.org/10.1016/j.jval.2019.08.012

Ejemplares similares

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
por: Fawsitt, Christopher G., et al.
Publicado: (2019)

Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients
por: Calabrese, Martin J., et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients
por: Asil, Mehmet, et al.
Publicado: (2016)

Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data
por: Andres, Jennifer, et al.
Publicado: (2018)

The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States
por: Elbasha, E. H., et al.
Publicado: (2016)

Primary hepatic angiosarcoma with noncirrhotic portal hypertension: A case report
por: Wu, Xuwei, et al.
Publicado: (2023)

Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report
por: Begovac, Josip, et al.
Publicado: (2018)

Idiopathic Noncirrhotic Portal Hypertension: An Appraisal
por: Lee, Hwajeong, et al.
Publicado: (2016)

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
por: Ageno, Walter, et al.
Publicado: (2022)

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
por: Lu, Yun, et al.
Publicado: (2018)

Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT
por: Hollingworth, William, et al.
Publicado: (2019)

Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension in Noncirrhotic Patients with Portal Cavernoma
por: Luo, Xuefeng, et al.
Publicado: (2014)

Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood
por: Kievit, Linda, et al.
Publicado: (2018)

Idiopathic noncirrhotic portal hypertension: current perspectives
por: Riggio, Oliviero, et al.
Publicado: (2016)

Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
por: Suarez, Oscar, et al.
Publicado: (2018)

HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
por: Grasso, Alessandro, et al.
Publicado: (2015)

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
por: Xu, Xiaoyuan, et al.
Publicado: (2019)

Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B
por: Pacheco, Sidelcina Rugieri, et al.
Publicado: (2017)

Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
por: Maunye, Tshegofatso K., et al.
Publicado: (2023)

Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus
por: Ahmad, Ayesha K., et al.
Publicado: (2019)

Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report
por: Alexopoulou, Alexandra, et al.
Publicado: (2019)

Treatment of Noncirrhotic Portal Hypertension Secondary to Portal Vein Thrombosis With Endovascular Mesocaval Shunt Creation
por: Phatharacharukul, Parkpoom, et al.
Publicado: (2020)

Noncirrhotic Portal Vein Thrombosis Presenting with Hepatic Encephalopathy Due to Polycythemia Vera and MRI Findings
por: GÖKÇE ÇOKAL, Burcu, et al.
Publicado: (2017)

Evidence Synthesis for Decision Making 5: The Baseline Natural History Model
por: Dias, Sofia, et al.
Publicado: (2013)

Transhepatic embolization of a congenital intrahepatic portosystemic shunt for the treatment of hepatic encephalopathy in a noncirrhotic patient using Amplatzer vascular plug device
por: Brader, Rachel Ann, et al.
Publicado: (2017)

Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area
por: Shim, Chang Woo, et al.
Publicado: (2017)

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus
por: Wang, Ye, et al.
Publicado: (2015)

Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012
por: Yeh, Chau-Ting, et al.
Publicado: (2017)

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile
por: Vargas, Constanza L., et al.
Publicado: (2015)

Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension
por: Etzion, Ohad, et al.
Publicado: (2018)

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy
por: Akpo, Essè Ifèbi Hervé, et al.
Publicado: (2015)

Splenic Marginal Zone Lymphoma in the Setting of Noncirrhotic Portal Hypertension
por: Ratnayake, Saman, et al.
Publicado: (2015)

Challenging liver lesions in noncirrhotic patients: Report of three cases
por: Franceschini, Tania, et al.
Publicado: (2019)

Persistent Encephalopathy in a Noncirrhotic Patient: Do not Shun This Shunt
por: Kassamali, Farah, et al.
Publicado: (2020)

Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts
por: Davies, Anna, et al.
Publicado: (2013)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
por: Lee, Han Ah, et al.
Publicado: (2023)

Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment
por: Heimgartner, Benjamin, et al.
Publicado: (2016)

Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics
por: Zeng, Wenjiao, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ift8m9k63ecmfrr1m73dai9t8i